Kura Oncology melaporkan kemajuan dengan ziftomenib pada Q2 2024 oleh Investing.com

and preclinical data suggest that menin inhibitors may enhance the efficacy of KIT inhibitors in GIST. We are excited to explore the potential of ziftomenib in combination with imatinib in patients with advanced GIST, with the goal of providing a new treatment option for this patient population. Despite the financial losses reported for the quarter, … Baca Selengkapnya